Leads Biolabs’ Anti-Cancer Antibody LBL-034 Receives Orphan Drug Designation from the US FDA for Multiple Myeloma Treatment

NANJING, China, Nov. 6, 2024 — On November 1, Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as “Leads Biolabs”) announced that LBL-034, a humanized bispecific T-cell engaging antibody targeting both GPRC5D and CD3 which is independently developed by Leads Biolabs with global intellectual property rights for treatment of multiple…

AMPCO METAL Expands Capabilities and Customer Offerings through Schmelzmetall Group Acquisition

MARLY, Switzerland, Nov. 6, 2024 —  AMPCO METAL, a global leader in copper-based alloys, is pleased to announce its acquisition of Switzerland-based Schmelzmetall Group, a renowned producer of high-performance copper alloys. This strategic acquisition strengthens AMPCO METAL’s position in the industry and expands its offerings to better serve customers across…

China’s Official Response to Trump’s Win is Aloof, While Experts Say Beijing is Concerned

KAOHSIUNG, Taiwan — China's official response to President-elect Trump's victory was formulaic."Our policy towards the U.S. is consistent," foreign ministry spokesperson Mao Ning told reporters Wednesday afternoon. "We will continue to view and handle China-U.S. relations in accordance with the principles of mutual respect, peaceful co-existence and win-win cooperation." National Taiwan…